Corcept Therapeutics (CORT) Proxy filing summary

Executive summary

• Annual meeting scheduled for May 21, 2026, with voting on four key proposals, including director elections, auditor ratification, executive compensation, and an amendment to the 2024 Incentive Award Plan.

• Only stockholders of record as of April 9, 2026, are eligible to vote; 107,356,686 shares outstanding.

• Proxy materials are available online, and multiple voting methods are provided.

Voting matters and shareholder proposals

• Proposals include electing eight directors, ratifying Ernst & Young LLP as auditor, advisory approval of executive compensation, and amending the 2024 Incentive Award Plan to add 8 million shares and clarify plan language.

• Board recommends voting in favor of all proposals.

• Shareholder proposals for the 2027 meeting must be submitted by December 23, 2026.

Board of directors and corporate governance

• Eight director nominees, all current directors, with diverse backgrounds in biotech, finance, and operations.

• Seven of eight directors are independent; CEO is not independent.

• Board committees: Audit, Compensation, and Corporate Governance & Nominating, all composed of independent directors.

• Board separates CEO and Chairman roles; independent Chairman leads the board.